These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20927134

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW.
    Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
    [Abstract] [Full Text] [Related]

  • 3. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K, AML CG study group.
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
    Ko YC, Fang WH, Lin TC, Hou HA, Chen CY, Tien HF, Lin LI.
    Leuk Res; 2014 May; 38(5):625-31. PubMed ID: 24703161
    [Abstract] [Full Text] [Related]

  • 6. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K.
    J Clin Oncol; 2004 Feb 15; 22(4):624-33. PubMed ID: 14726504
    [Abstract] [Full Text] [Related]

  • 7. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.
    Clin Cancer Res; 2005 Feb 15; 11(4):1416-24. PubMed ID: 15746041
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA, Ahmed LM, Taha AM, Kamal O.
    Egypt J Immunol; 2008 Feb 15; 15(1):131-43. PubMed ID: 20306678
    [Abstract] [Full Text] [Related]

  • 9. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group.
    N Engl J Med; 2008 May 01; 358(18):1909-18. PubMed ID: 18450602
    [Abstract] [Full Text] [Related]

  • 10. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM, Aladle DA, Abousamra NK, Elghannam DM, Fawzy IM.
    Hematology; 2013 Mar 01; 18(2):61-8. PubMed ID: 22990006
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O, Barragán E, Bolufer P, Such E, Valencia A, Ibáñez M, Dolz S, de Juan I, Jiménez A, Gómez MT, Buño I, Martínez J, Cervera J, Montesinos P, Moscardó F, Sanz MÁ.
    Ann Hematol; 2012 Jan 01; 91(1):1-7. PubMed ID: 21538063
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
    Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T.
    Ann Hematol; 2014 Jun 01; 93(6):957-63. PubMed ID: 24441947
    [Abstract] [Full Text] [Related]

  • 16. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
    Fasan A, Alpermann T, Haferlach C, Grossmann V, Roller A, Kohlmann A, Eder C, Kern W, Haferlach T, Schnittger S.
    PLoS One; 2013 Jun 01; 8(2):e54365. PubMed ID: 23383300
    [Abstract] [Full Text] [Related]

  • 17. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.
    Musialik E, Bujko M, Kober P, Grygorowicz MA, Libura M, Przestrzelska M, Juszczyński P, Borg K, Florek I, Jakóbczyk M, Baranowska A, Siedlecki JA.
    Leuk Res; 2014 Jul 01; 38(7):850-6. PubMed ID: 24878001
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
    Li HY, Deng DH, Huang Y, Ye FH, Huang LL, Xiao Q, Zhang B, Ye BB, Lai YR, Mo ZN, Liu ZF.
    Eur J Haematol; 2015 May 01; 94(5):439-48. PubMed ID: 25227715
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors in AML in relation to (ab)normal karyotype.
    Stone RM.
    Best Pract Res Clin Haematol; 2009 Dec 01; 22(4):523-8. PubMed ID: 19959103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.